The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

Zamagni, Elena; Tacchetti, Paola; Deias, Paola

doi:10.3390/ph13120451

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a median follow-up of 26 months, the complete remission rates were 4.9%, 9.8%, and 0%, respectively. Based on these data, the ongoing randomized phase III AQUILA study (NCT03301220) is investigating the long dosing schedule in 360 high-risk SMM patients, comparing subcutaneous daratumumab for up to 39 cycles versus watch and wait [ 200 ]. Preliminary results look promising, although adequate follow-up is needed to detect the potential benefit on OS [ 201 ].…”

Section: Targeting MM Cells To Activate the Immune System: Monoclonal...mentioning

confidence: 99%

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

et al. 2023

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called “smoldering” MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution questionable. On the other hand, we currently know that changes in the bone marrow microenvironment (TME) could play a key role in MM evolution through a progressive shift towards a pro-inflammatory and immunosuppressive shape, which may drive cancer progression as well as clonal plasma cells migration, proliferation, survival, and drug resistance. Along this line, the major advancement in MM patients’ survival has been achieved by the introduction of microenvironment-oriented drugs (including immunomodulatory drugs and monoclonal antibodies). In this review, we summarized the role of the different components of the TME in MM evolution from MGUS as well as potential novel therapeutic targets/opportunities.

show abstract

Section: Targeting MM Cells To Activate the Immune System: Monoclonal...mentioning

confidence: 99%

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The treatment paradigm in MMis evolving with the introduction of various immunotherapies [ 2 ]. First came the monoclonal antibodies (mAbs), which represented a paradigm shift in treating all MM stages [ 3 , 4 , 5 , 6 , 7 ]. The initial mAbs included daratumumab, which targets CD38 on MM cells’ surface [ 8 , 9 ], and elotuzumab, which targets SLAMF7 [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Martino

Canale

Alati

et al. 2021

Cancers

View full text Add to dashboard Cite

Despite the improvement in survival outcomes, multiple myeloma (MM) remains an incurable disease. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R). In this paper, we describe several recent advances in the field of anti-BCMA CAR T-cell therapy and MM. Currently, available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Despite this, the main issues remain to be addressed. First of all, a significant proportion of patients eventually relapse. The potential strategy to prevent relapse includes sequential or combined infusion with CAR T-cells against targets other than BCMA, CAR T-cells with novel dual-targeting vector design, and BCMA expression upregulation. Another dark side of CART therapy is safety. Cytokine release syndrome (CRS) andneurologic toxicity are well-described adverse effects. In the MM trials, most CRS events tended to be grade 1 or 2, with fewer patients experiencing grade 3 or higher. Another critical point is the extended timeline of the manufacturing process. Allo-CARs offers the potential for scalable manufacturing for on-demand treatment with shorter waiting days. Another issue is undoubtedly going to be access to this therapy. Currently, only a few academic centers can perform these procedures. Recognizing these issues, the excellent response with BCMA-targeted CAR T-cell therapy makes it a treatment strategy of great promise.

show abstract

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

Cited by 2 publications

References 42 publications

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Contact Info

Product

Resources

About